Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first-line non-small cell lung cancer treated with chemotherapy with or without bevacizumab

Journal of Clinical Pharmacology

Volumn 54, Issue 3, 2014, Pages 253-257

  Claret, Laurent ^a   Gupta, Manish ^b   Han, Kelong ^b   Joshi, Amita ^b   Sarapa, Nenad ^c   He, Jing ^d   Powell, Bob ^e   Bruno, René ^a  

^a A Certara Company   (France)

^b GENENTECH INC   (United States)

^c Hoffman LA Roche   (United States)

^d Roche Product Development in Asia Pacific   (China)

^e Pharmaceutical Research and Early Development (PRED) Roche   (China)

Author keywords

ethnic differences; NSCLC; overall survival; predictive model; progression free survival; response categories

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHINESE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ETHNIC DIFFERENCE; HAZARD RATIO; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL PREDICTION; TREATMENT OUTCOME; TUMOR VOLUME;

ETHNIC DIFFERENCES; NSCLC; OVERALL SURVIVAL; PREDICTIVE MODEL; PROGRESSION FREE SURVIVAL; RESPONSE CATEGORIES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CONTINENTAL POPULATION GROUPS; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; PACLITAXEL; SERUM ALBUMIN; TREATMENT OUTCOME;

EID: 84898648618     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.191     Document Type: Article

References (23)

1. Claret L, Girard P, O'shaughnessy J, et al. Model-based predictions of expected anti-tumor response and survival in phase III studies based on phase II data of an investigational agent. J Clin Oncol. 2006; 24: 6025 (abstract).
2. Claret L, Girard P, Hoff PM, et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol. 2009; 27: 4103-4108.
3. Wang Y, Sung C, Dartois C, et al. Elucidation of relationship between tumor size and survival in non-small cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther. 2009; 86: 167-174.
4. Bruno R, Jonsson F, Zaki M, et al. Simulation of clinical outcome for pomalidomide plus low-dose dexamethasone in patients with refractory multiple myeloma based on week 8 M-protein response. Blood 2011; 118: 1881 (abstract).
5. Lara PN Jr, Redman MW, Kelly K, et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol. 2008; 26: 463-4467.
6. An MW, Mandrekar SJ, Branda ME, et al. Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials. Clin Cancer Res. 2011; 17: 6592-6599.
7. Stein WD, Gulley JL, Schlom J, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res. 2010; 17: 907-917.
8. Claret L, Gupta M, Han K, et al. Evaluation of tumor size response metrics to predict overall survival in western and Chinese patients with first line metastatic colorectal cancer. J Clin Oncol. 2013; 31: 2110-2114.
9. Lavin PT., An alternative model for the evaluation of antitumor activity. Cancer Clin Trials. 1981; 4: 451-457.
10. Karrison TG, Maitland ML, Stadler WM, Ratain MJ., Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small-cell lung cancer. J Natl Cancer Inst. 2007; 99: 1455-1461.
11. Bruno R, Claret L., On the use of change in tumor size to predict survival in clinical oncology studies: toward a new paradigm to design and evaluate Phase II studies. Clin Pharmacol Ther. 2009; 86: 136-138.
12. Blumenschein GR Jr, Kabbinavar F, Menon H, et al. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2011; 22: 2057-2067.
13. Scagliotti G, Vynnychenko I, Ichinoseet Y, et al. An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol. 2011; 30: 2829-2836.
14. Claret L, Lu JF, Bruno R, et al. Simulations using a public domain drug-disease modeling framework and Phase II data predict Phase III survival outcome in first-line non-small-cell lung cancer (NSCLC). Clin Pharmacol Ther. 2012; 92: 631-634.
15. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New Engl J Med. 2006; 355: 2542-2550. (Pubitemid 44917502)
16. Crinò L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010; 11: 733-740.
17. Tsai CM, Au JS, Chang GC, et al. Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced non-squamous NSCLC. J Thorac Oncol. 2011; 6: 1092-1097.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205-216. (Pubitemid 30099779)
19. McMillan DC., The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013; 39: 534-540.
20. Claret L, Gupta M, Joshi A, et al. Evaluation of tumor size response metrics to predict survival and progression free survival in first line metastatic colorectal cancer. PAGE. 2012; 21: 2328 (abstract).
21. Dodd LE, Korn EL, Freidlin B, et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense ? J Clin Oncol. 2008; 26: 3791-3796.
22. Bhattacharya S, Fyfe G, Gray RJ, Sargent DJ., Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. J Clin Oncol. 2009; 27: 5958-5964.
23. Bruno R, Lu JF, Sun YN, Claret L., A Modeling and simulation framework to support early clinical drug development decisions in oncology. J Clin Pharmacol. 2011; 51: 6-8.